Schonfeld Strategic Advisors’s Denali Therapeutics DNLI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-226,203	Closed	-$3.28M	–	2168
2025 Q3	$3.28M	Buy	+226,203	New	+$3.25M	0.02%	792
2024 Q3	–	Sell	-163,074	Closed	-$3.79M	–	2121
2024 Q2	$3.79M	Buy	+163,074	New	+$3.13M	0.02%	652
2024 Q1	–	Sell	-18,327	Closed	-$393K	–	2135
2023 Q4	$393K	Buy	+18,327	New	+$363K	﹤0.01%	1357
2018 Q1	–	Sell	-47,492	Closed	-$743K	–	806
2017 Q4	$743K	Buy	+47,492	New	+$854K	0.06%	366

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schonfeld Strategic Advisors's DNLI Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 226,203 shares — an estimated $3.28M sold.

Schonfeld Strategic Advisors first reported a position in DNLI in Q4 2017 and held it in 4 quarters. The position peaked at $3.79M in Q2 2024. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Schonfeld Strategic Advisors reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 226,203 Denali Therapeutics shares in Q4 2025, an estimated $3.28M.
Schonfeld Strategic Advisors first reported a position in Denali Therapeutics in Q4 2017 and held it in 4 quarters.
Schonfeld Strategic Advisors's Denali Therapeutics position peaked at $3.79M in Q2 2024.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.